Background

Jack joined the Burnet Institute in 2019 to work on multiple projects in the Eliminate Hepatitis C Partnership.

He completed his honours with the Burnet in 2017. His thesis explored pathways to increase access to hepatitis C treatment in pharmacies that provide opioid substitution therapy.

Jack has interests in both qualitative and quantitative research, AOD harm reduction, mental health, and blood-borne viruses.

Qualifications

• 2017: BHSc (Public Health Hons), La Trobe University, Melbourne, Australia
• 2016: BHSc, La Trobe University, 2016, Melbourne, Australia

Projects (1)

Current (1)

• 

  Feasibility study for a potential medically supervised injecting centre/drug consumption service for the ACT

Publications (5)

2021 (3)

• Health service utilisation and experiences of stigma among people who inject drugs in Melbourne, Australia.
  Djordjevic F, Ryan K, Gunn J, Brener L, O'Keefe D, Draper B, Schroeder S, Gold J, Treloar C, Broady T, Dietze P, Hellard M, Pedrana A
  J Viral Hepat. 2021 Sep; Epub ahead of print
• Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
  Gunn J, McNally S, Ryan J, Layton C, Bryant M, Walker S, O'Mahony C, Pedrana A.
  Int J Drug Policy. 2021 Jul; 96:103387
• Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
  Chan K, Elsum I, Gold J, Layton C, Accadia L, Bryant M, Gunn J, Djordjevic F, Purcell I, Dicka J, Forrest M, Crawford S, Hellard M, Pedrana A; Eliminate Hepatitis C Partnership
  J Viral Hepat. 2021 Jan; 28(3):569-572

2020 (1)

• Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
  Gunn J, Higgs P
  Res Social Adm Pharm. 2020 Jan; 16(9):1298-1301

2019 (1)

• Pharmacy-led hepatitis C treatment pathways to help ensure elimination.
  Gunn J, Higgs P
  Lancet Gastroenterol Hepatol. 2019 Jan; 4(1):12-13